The present invention relates to a reaction platform, which comprises: a machine body with a bottom plate for placing non-porous substrates; and a coater module configured on the top of the machine body and capable of maintaining a preset of a predetermined height for moving along the surface of non-porous substrate, wherein the coater module has one or more slits, and a target liquid can be directly injected or sucking in from the outside of the coater module through the slit, and spreading the target liquid onto a surface of the non-porous substrate while moving along the non-porous substrate; wherein the surface of the non-porous substrate has a target to be coated. The reaction platform of the present invention can not only save time, labor and cost, but also have accurate and reproducible experimental results, showing better results than traditional methods.

Methods, systems, and compositions featuring a solid, dissolvable reagent composition for delivering the reagent, such as an antibody, probe, chromogen, etc., to a sample. The present invention also features methods of producing said compositions, and automated systems featuring the use of the solid, dissolvable reagent compositions. The solid, dissolvable reagent composition may comprise a water-soluble polymer film, such as a polyvinyl alcohol film, infused with the reagent, wherein when applied to the sample, the water-soluble polymer film with reagent contacts the sample (e.g., tissue) and dissolves.

An AKR1C3 detection method, and a diagnostic kit for detecting AKR1C3 and use thereof. The AKR1C3 detection method includes the following steps: treating a formalin-fixed paraffin-embedded human tissue specimen sequentially using an organic solvent, an alcohol, and water; performing antigen retrieval on the treated formalin-fixed paraffin-embedded human tissue specimen in the presence of an antigen retrieval solution; co-incubating the antigen-retrieved formalin-fixed paraffin-embedded human tissue specimen with a blocking buffer to block a non-specific antigen; mixing the blocked formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of AKR1C3 monoclonal antibody solution for primary antibody incubation, and mixing the primary antibody-incubated formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of a secondary antibody solution for secondary antibody incubation. The AKR1C3 detection method can be applied to the detection of AKR1C3 expression levels in various cancer tumor tissues and is stable in dyeing results, and has good sensitivity, precision and consistency.

The present disclosure relates to a method of providing information for predicting a treatment response to an immune checkpoint inhibitor in a cancer patient by using multiplex immunohistochemistry, wherein, by performing multiplex immunohistochemistry on tumor tissue of a cancer patient to measure an expression level of an immune checkpoint molecule by an automated method, the treatment response to the immune checkpoint inhibitor in the cancer patient can be accurately and quickly predicted. In addition, unlike existing methods using single immunohistochemistry, the disclosed method can reduce errors of an inspector by analyzing markers simultaneously expressed in a single cell and evaluating the same by an automated method, and thus will be widely used as a companion diagnostic method for an immune checkpoint inhibitor.

A method of making a tissue reference control block is disclosed wherein cancer cells are selected with a known positivity or negativity for a specific marker and cancer cells are grown to a certain phase. The cancer cells are screened for an expression of the specific marker and the screened cancer cells are mixed with stromal cells and co-cultured in a bio-reactor bag. A spheroid grown from the co-cultured mixture of cells is harvested, fixed, and embedded in a core of a paraffin block.

The disclosure relates to antigen binding domains that specifically bind to a major histocompatibility class I (MHC I) complex comprising an a chain encoded by HLA-A*11 alleles. The disclosure further relates to antibodies and receptors comprising said antigen binding domains, and their use in diagnostics and adoptive cell therapy.

The present invention relates to methods and compositions for sequential multidimensional immunohistochemical analyses of tissues.

The present disclosure is generally directed to compositions and methods related to USP15 inhibitors. More particularly, the present disclosure relates to methods of regulating CRL4.sup.CRBN-USP15 pathway (previously referred to as the CRL4.sup.CRBN-p97 pathway) and glutamine synthetase levels and methods of treating diseases such as cancer via administration of USP15 inhibitors.

The present disclosure demonstrates that the amount of soluble folate receptor alpha (FR?) present in a cancer patient is a strong predictor of the efficacy of FR?-targeting therapies. Surprisingly, increased levels of soluble FR? are associated with improved outcomes. Accordingly, the present disclosure provides methods for treating cancer in patients with soluble FR? and methods for identifying a cancer as likely to respond to an anti-FR? therapy based on soluble FR? levels.

The present invention relates to the technical field of computers, and more particularly, to a method for generating training data based on immunohistochemistry, and a storage device. The method for generating the training data based on immunohistochemistry includes the following steps: performing immunohistochemical staining on a target object through different antibodies; labeling the target object according to staining results; and generating training data according to labeling results. According to the method, a pathologist can label a tissue or cell of interest rapidly and conveniently without performing labeling through H&E slicing in combination with histomorphology. In addition, since this tissue or cell is labeled based on an immunohistochemistry technology of a gold standard, this labeling is more accurate compared with manual labeling performed through H&E slicing in combination with histomorphology.